{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:47:13Z","timestamp":1747205233001,"version":"3.40.5"},"posted":{"date-parts":[[2020,11,11]]},"group-title":"In Review","reference-count":0,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2020,7,17]]},"abstract":"<title>Abstract<\/title>\n        <p><bold>Background: <\/bold>Esophageal cancer (ECa) is the 7<sup>th<\/sup> most incident cancer and the 6<sup>th<\/sup> leading cause of cancer-related death. Most patients are diagnosed with locally advanced or metastatic disease, enduring poor survival. Biomarkers enabling early cancer detection may improve patient management, treatment effectiveness, and survival, are urgently needed. In this context, epigenetic-based biomarkers such as DNA methylation are potential candidates.     <bold>Methods: <\/bold>Herein, we sought to identify and validate DNA methylation-based biomarkers for early detection and prediction of response to therapy in ECa patients. Promoter methylation levels were assessed in a series of treatment-na\u00efve ECa, post-neoadjuvant treatment ECa, and normal esophagus tissues, using quantitative methylation-specific PCR for <italic>COL14A1<\/italic>, <italic>GPX3,<\/italic> and <italic>ZNF569<\/italic>.       <bold>Results: <\/bold><italic>ZNF569<\/italic> methylation (<italic>ZNF569me) <\/italic>levels significantly differed between ECa and normal samples (<italic>p<\/italic>&lt;0.001). Moreover, <italic>COL14A1<\/italic> methylation (<italic>COL14A1me) <\/italic>and <italic>GPX3<\/italic> methylation (<italic>GPX3me) <\/italic>levels discriminated adenocarcinomas and squamous cell carcinomas, respectively, from normal samples (<italic>p<\/italic>=0.002 and <italic>p<\/italic>=0.009, respectively). <italic>COL14A1me<\/italic> &amp; <italic>ZNF569me<\/italic> accurately identified adenocarcinomas (82.29%) whereas <italic>GPX3me &amp; ZNF569me<\/italic> identified squamous cell carcinomas with 81.73% accuracy. Furthermore, <italic>ZNF569me<\/italic> and <italic>GPX3me<\/italic> levels significantly differed between normal and pre-treated ECa.    <bold>Conclusion: <\/bold>The biomarker potential of a specific panel of methylated genes for ECa was confirmed. These might prove useful for early detection and might allow for the identification of minimal residual disease after adjuvant therapy.<\/p>","DOI":"10.21203\/rs.3.rs-44848\/v3","type":"posted-content","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T12:46:28Z","timestamp":1605098788000},"source":"Crossref","is-referenced-by-count":0,"title":["A DNA Methylation-based Test for Esophageal Cancer Detection"],"prefix":"10.21203","author":[{"given":"Sofia","family":"Salta","sequence":"first","affiliation":[{"name":"Instituto Portugues de Oncologia do Porto Francisco Gentil EPE"}]},{"given":"Catarina","family":"Macedo-Silva","sequence":"additional","affiliation":[{"name":"Instituto Portugues de Oncologia do Porto Francisco Gentil EPE"}]},{"given":"Vera","family":"Miranda-Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Instituto Portugues de Oncologia do Porto Francisco Gentil EPE"}]},{"given":"Nair","family":"Lopes","sequence":"additional","affiliation":[{"name":"Instituto Portugues de Oncologia do Porto Francisco Gentil EPE"}]},{"given":"Davide","family":"Gigliano","sequence":"additional","affiliation":[{"name":"Instituto Portugues de Oncologia do Porto Francisco Gentil EPE"}]},{"given":"Rita","family":"Guimar\u00e3es","sequence":"additional","affiliation":[{"name":"Instituto Portugues de Oncologia do Porto Francisco Gentil EPE"}]},{"given":"M\u00f3nica","family":"Farinha","sequence":"additional","affiliation":[{"name":"Instituto Portugues de Oncologia do Porto Francisco Gentil EPE"}]},{"given":"Olga","family":"Sousa","sequence":"additional","affiliation":[{"name":"Instituto Portugues de Oncologia do Porto Francisco Gentil EPE"}]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"Instituto Portugues de Oncologia do Porto Francisco Gentil EPE"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4186-5345","authenticated-orcid":false,"given":"Carmen","family":"Jeronimo","sequence":"additional","affiliation":[{"name":"Portuguese Oncology Institute of Porto (IPO Porto)"}]}],"member":"297","container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-44848\/v3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-44848\/v3.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T23:51:56Z","timestamp":1659052316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-44848\/v3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-44848\/v3","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s40364-020-00248-7","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2020,11,11]]},"subtype":"preprint"}}